Genetic Contribution to Metastatic Prostate Cancer.

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Metastatic prostate cancer (mPC) shows a higher prevalence of germline pathogenic and likely pathogenic variants (mutations) in DNA repair genes than previously recognized.
• These genetic alterations play a crucial role in prostate cancer initiation and progression to metastatic disease.
• Specific gene dysfunctions are increasingly implicated in the development and evolution of mPC.

Purpose of the Study:

• To review key literature on individual DNA repair genes implicated in prostate cancer.
• To highlight BRCA2 as the most frequently altered gene in the metastatic prostate cancer setting.
• To discuss the importance of diverse and representative inclusion in research and clinical management strategies for at-risk populations.

Main Methods:

• Literature review of studies investigating germline variants in DNA repair genes in prostate cancer.
• Analysis of the prevalence and impact of specific gene mutations in the metastatic setting.
• Examination of current management strategies and future directions for carrier populations.

Main Results:

• Germline pathogenic variants in DNA repair genes are more prevalent in metastatic prostate cancer patients than in the general population.
• BRCA2 is identified as the most commonly altered gene in metastatic prostate cancer.
• Evidence suggests a significant role for these variants in prostate cancer pathogenesis and metastasis.

Conclusions:

• Germline DNA repair gene variants are a critical factor in metastatic prostate cancer.
• Targeted management strategies for at-risk carrier populations are essential for maximizing clinical benefit.
• Ensuring diverse and representative inclusion in studies is vital for advancing care and understanding.